Small Molecules

02 Sep 2020 Janssen to Discontinue Pimodivir Influenza Development Program
02 Sep 2020 Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients
02 Sep 2020 Da Volterra Announces Positive Results from a Phase 1 Clinical Trial Evaluating DAV132 in Healthy Volunteers Receiving ß-lactam Antibiotics
02 Sep 2020 Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
02 Sep 2020 U.S. Food and Drug Administration Approves Onureg® (azacitidine tablets) , a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
01 Sep 2020 Mirum Pharmaceuticals Initiates Rolling Submission of a New Drug Application for Maralixibat for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome and Launches Expanded Access Program
01 Sep 2020 Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
01 Sep 2020 Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720
01 Sep 2020 Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder
01 Sep 2020 Rodeo Therapeutics Nominates First-in-Class Oral Development Candidate for Inflammatory Bowel Disease
01 Sep 2020 FDA grants Priority Review of melflufen for patients with triple-class refractory multiple myeloma
30 Aug 2020 Fortress Biotech Announces Positive Topline Clinical Efficacy Results for CUTX-101, Copper Histidinate, for the Treatment of Menkes Disease
30 Aug 2020 Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
30 Aug 2020 Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
30 Aug 2020 Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress™ 2020
30 Aug 2020 Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115, a Potential First-in-Class Treatment for Insomnia Disorder, at 34th Annual Sleep Meeting
30 Aug 2020 Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19
28 Aug 2020 Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020
28 Aug 2020 Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
26 Aug 2020 Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis
26 Aug 2020 NewAmsterdam Pharma Acquires Obicetrapib from Amgen
26 Aug 2020 Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases
26 Aug 2020 Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
25 Aug 2020 AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis
25 Aug 2020 Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up